Available Clinical Trials

Nevada Cancer Institute offers many diverse options for the treatment of cancer. For more information about any of the trials listed below, please contact the clinical researcher listed with each trial.

» Phase I ( All Tumor Types)
» Hematology
» Breast Cancer

» Lung Cancer and Mesothelioma
» Genitourinary Cancers

» Kidney Cancer
»Bladder Cancer
» Melanoma
» Gastrointestinal Cancers

» Return to Clinical Trials main

Phase I ( All Tumor Types)

All Solid Tumors		Annette (702) 822-5177	Inhibition of DNA Methylation by Decitabine with Escalating Doses of Sub-Q Pegylated (PEG) Interferon-alfa 2B (PEG-Intron)
All Solid Tumors		Jennifer (702) 822-5356	AMG 386 with AMG 706, AMG 386 with Bevacizumab, AMG 386 with Sorafenib, and AMG 386 with Sunitinib in Adult Patients with Advanced Solid Tumors
All Solid Tumors		Dianna (702) 822-5483	Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
All Solid Tumors		Annette (702) 822-5177	ARQ 621 in Adult Patients with Metastatic Solid Tumors
All Solid Tumors		Annette (702) 822-5177	MPC-3100 in patients with refractory or relapsed cancer
All Solid Tumors		Dianna (702) 822-5483	BEZ235, administered orally on a continous daily dosing schedule in adult patient with advanced solid malignancies including patients with advanced breast cancer
All Solid Tumors		Zeeshan (702) 822-5200	Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastasis Starting Zoledronic Acid Treatment

Hematology

Lymphocytic Leukemia		Dianna (702) 822-5483	TRU-016 in Patients with Previously Treated Chronic Lymphocytic Leukemia
Lymphoma		Elizabeth (702) 822-5375	RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab chemotherapy
Multiple Myeloma		Elizabeth (702) 822-5375	oral LBH589 and IV bortezomib in adult patients with multiple myeloma
Lymphoma; Lymphocytic Luekemia		Elizabeth (702) 822-5375	Intratumoral Poly-ICLC plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma

Breast Cancer

Breast - Female		Shamine (702) 822-5142	Phase III Study of Doxorubicin/Cyclophosphamide (AC) followed by Ixabepilone vs. AC followed by Paclitaxel in Patients with Triple-Negative Early-Stage Breast Cancer
Breast - Female		Shamine (702) 822-5142	daily everolimus in combination with trastuzumab and vinorelbine, in pretread women with HER2/neu over-expressing locally advanced or metastatic breast cancer
Breast - Female		Zeeshan (702) 822-5200	Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study: A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
Breast - Female		Shamine (702) 822-5142	Phase III Study of Doxorubicin/Cyclophosphamide (AC) followed by Ixabepilone vs. AC followed by Paclitaxel in Patients with Triple-Negative Early-Stage Breast Cancer

Lung Cancer and Mesothelioma

Non Small Cell Lung Cancer		Zeeshan (702) 822-5200	A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) – IIIA Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer		Zeeshan (702) 822-5200	Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer		Christine (702) 822-5456	CBP501, pemetrexed and cisplatin as first line treatment in patients with locally advanced (stage IIIB with malignant pleural effusion or pericardial effusion) or metastatic (stage IV) non-squamous non small cell lung cancer (NSCLC)
Non Small Cell Lung Cancer		Christine (702) 822-5456	STA-9090 in Subjects with Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer		Christine (702) 822-5456	ASA404 in combination with docetaxel in second-line treatment of patients with advanced or metastatic (Stage IIIb/IV) non-small cell lung cancer (NSCLC)
Non Small Cell Lung Cancer		Shamine (702) 822-5142	Genetic Epidemiology of Lung Cancer I (GELCC)
Non Small Cell Lung Cancer		Shamine (702) 822-5142	Genetic Epidemiology of Lung Cancer I (GELCC)
Mesothelioma		Christine (702) 822-5456	CBP501, pemetrexed and cisplatin in patients with advanced solid tumors and in chemotherapy-naïve patients with malignant pleural mesothelioma

Genitourinary Cancers

Bladder		Jacky (702) 822-5393	TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma
Prostate		Jacky (702) 822-5393	Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy
Prostate		Carol (702) 822-5449	Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Prostate		Jacky (702) 822-5393	Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients.
Prostate		Carol (702) 822-5449	Adjuvant 3DCRT/IMRT in combination with androgen suppression and docetaxel for high risk prostate cancer patients post prostatectomy
Prostate		Zeeshan (702) 822-5200	Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone
Prostate		Zeeshan (702) 822-5200	Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
Prostate		Zeeshan (702) 822-5200	ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
Prostate		Carol (702) 822-5449	Analysis of circulating tumor cells in prostate cancer predicting response to taxanes.
Prostate		Carol (702) 822-5449	Analysis of circulating tumor cells in prostate cancer predicting response to taxanes

Kidney Cancer

Kidney		Carol (702) 822-5449	bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney
Kidney		Yolande (702) 822-5484	AXITINIB (AG-013736) with or without dose titration in patients with metastatic renal cell carcinoma

Bladder Cancer

Bladder		Carol (702) 822-5449	An open-label, single-arm, Phase II trial of intravenous BI 6727 in patients with locally advanced, metastatic or recurrent urothelial cancer of the bladder, renal pelvis, or ureters after failure of prior chemotherapy
Bladder		Zeeshan (702) 822-5200	Study comparing Gemcitabine, cisplatin and bevacizumab to Gemcitabine, cisplatin and placebo in patients with advanced transitional cell carcinoma

Melanoma

Melanoma		Yolande (702) 822-5484	Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma
Melanoma		Yolande (702) 822-5484	ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma

Gastrointestinal Cancers

Colon		Zeeshan (702) 822-5200	5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
Rectal		Zeeshan (702) 822-5200	Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum
Colon; Rectal		Zeeshan (702) 822-5200	Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarinoma of the Colon or Rectum
Liver		Shamine (702) 822-5142	Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)

Contact Us

Please contact us with any questions or comments.

(702) 822-LIFE

(866) 621-NVCI

Latest News

NVCI Launches ARRA-Funded Plus One Program for New Nursing Grads to Deliver Competitive Edge in Job Search

Nevada Cancer Institute Hires New Faculty Members

NVCI and Siemens Foundation Announce 2010 Nursing Scholarship Winners

Maps & Directions

To visit our state-of-the-art, flagship facility click here.

NVCI Bus Stop